Ngwaahịa

Niacin (nicotinic acid) dị ka monotherapy nwere ike ibelata ihe ize ndụ nke ọrịa vaskụla, mana usoro ya ka ọ na-arụ ụka, ma ọ nwere ike ọ gaghị adabere na mmetụta na-agbanwe lipid systemic.N'oge na-adịbeghị anya egosiri niacin iji melite ọrụ endothelial na vaskụla vaskụla, na-adabereghị na mgbazi dyslipidemia, n'ụdị òké nke mmerụ ahụ na ọrịa metabolic.Dị ka ihe nwere ike ịmalite biosynthetic maka NAD (+), niacin nwere ike nweta uru vaskụla ndị a site na NAD(+) -based, sirtuin (SIRT) nzaghachi na-agbaziri.N'aka nke ọzọ, niacin nwere ike ime ihe site n'aka onye na-anabata ya, GPR109A, iji kwalite ọrụ endothelial, ọ bụ ezie na sel endothelial amabeghị ka ọ na-egosipụta ihe nnata a.Anyị chere na niacin na-emeziwanye ọrụ sel endothelial ozugbo n'oge ọnọdụ lipotoxic ma chọọ ịchọpụta usoro nwere ike itinye aka na ya. Ntinye uche dị ntakịrị nke niacin (10 μM), ma ọ bụ nicotinamide mononucleotide (NMN) (1 μM), ihe mbido NAD (+) kpọmkwem.Ọ bụ ezie na ma niacin na NMN kwalitere nhazi tube HMVEC n'oge oke ibu, naanị NMN mụbara NAD (+) cellular na ọrụ SIRT1.Anyị gara n'ihu hụ na HMVEC express GRP109A.Ejikwa acifran ma ọ bụ MK-1903 rụọ ọrụ nke onye na-anabata ihe a na-emeziwanye ihe na-eme ka niacin na-emeziwanye na nhazi tube HMVEC, ebe GPR109A siRNA na-ebelata mmetụta nke niacin.Niacin, na obere ntinye uche, na-eme ka ọrụ HMVEC angiogenic dị n'okpuru ọnọdụ lipotoxic, ma eleghị anya na-adabere na NAD. +) biosynthesis na SIRT1 ịgbalite, kama site na ịgbalite nnabata nke niacin.